🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia

RecruitingNAAges 18 Years - 80 YearsAllAir Force Military Medical University, China
NCT06756139 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Functional dyspepsia (FD) is a common gastrointestinal disease, which is associated with decreased life quality and increased medical cost. Antipsychotic drugs were demonstrated to be effective in relieving symptoms in FD patients, especially for patients with refractory FD. However, the use of those drugs was associated with obvious adverse events. Cognitive behavioral therapy (CBT) has extensive applications and exhibited potential treatment effects in clinical practices, especially for treating anxiety, depression, pain or stress disorders. Several previous RCT studies have confirmed the effects of psychological intervention on improving dyspepsia in FD patients. Our hypothesis was that 8-week smartphone-based CBT would be non-inferior to conventional pharmacotherapy in reducing FD-related symptoms in patients with refactory FD.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-80 2. Refractory functional dyspepsia (patients with Rome IV functional dyspepsia remained symptomatic after treatment of 8 weeks of proton pump inhibitor and 4 weeks of prokinetics) 3. Negative or unrelated-to-FD symptom findings of gastroscopy, upper abdominal ultrasound, Hp test and routine blood tests within the past 1 year. Exclusion Criteria: 1. Severe mental illness (PHQ-9 ≥20 or GAD-7 ≥15) or suicidal ideation; 2. Known hp infection, active gastrointestinal peptic ulcer, cholecystitis, gallstones, suspected or known bowel obstruction, gastroparesis, major gastrointestinal surgery etc.; 3. Known or suspected malignant tumor, significant heart/brain/liver/kidney diseases, obvious hematologic abnormalities or endocrine diseases etc., which may be -related to FD symptoms; 4. Known or suspected drug-related FD (e.g.NSAIDs-related FD); 5. Unable to access to mobile networks or unable to manage mobile APP properly. 6. Allergy or other contradictions to flupenthixol or melitracen 7. Taking any antipsychotics drugs or CBT interference within 12 weeks 8. Pregnant or lactating women; 9. Unable to provide informed consent.
💊

What it tests

  • cognitive behavioural therapy mobile application
  • Flupentixol and Melitracen Tablets
📍

Where

7 sites
Hainan General Hospital (Hainan Affifiliated Hospital ofHainan Medical University)
Haikou, China
Air Force Military Medical University, China
Xi'an, China
Shaanxi Second People's Hospital
Xi'an, China
Tangdu Hospital
Xi'an, China
Xi'an 986 Hospital
Xi'an, China
Xi'an People's Hospital
Xi'an, China
Mianyang Third Hospital
Mianyang, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy